You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCR inhibitors

Showing 1 - 25 of 4,371
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)

Active, not recruiting
  • Recurrent Chronic Lymphoid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Myeloproliferative Tumor, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (Online

Recruiting
  • Myeloproliferative Neoplasm
  • +2 more
  • Online Mindfulness Meditation
  • Internet-Based Webinars
  • San Francisco, California
    University of California San Francisco
Aug 9, 2022

Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

Not yet recruiting
  • Tyrosine Kinase Inhibitors
  • Chronic Myeloid Leukemia
  • treatment of TKI in CML
  • Poitiers, France
    Chu Poitiers
Feb 21, 2023

Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and

Completed
  • Leukemia
  • No Intervention
  • Cambridge, Massachusetts
    Takeda
Feb 28, 2023

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy

Recruiting
  • Chronic Myeloid Leukemia
  • Pisa, Italy
  • +1 more
Jan 4, 2022

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Study Conducted Among Patients With CML

Completed
  • Chronic Myeloid Leukemia
  • Tyrosine Kinase Inhibitors (TKIs)
  • East Hanover, New Jersey
    Novartis Investigative Site
Jul 25, 2022

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug Trial in Czechia (Imatinib withdrawal, Dasatinib, Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Withdrawal;Drug
  • Imatinib withdrawal
  • +2 more
  • Brno, Czechia
  • +7 more
Aug 24, 2022

Chronic Myeloid Leukemia in Chronic Phase Trial in Belgium, Germany (LBH589)

Terminated
Has Results
  • Chronic Myeloid Leukemia in Chronic Phase
  • Bruxelles, Belgium
  • +9 more
Jul 14, 2021

Leukemia,Myeloid, Chronic Trial in France (Blood and bone marrow sample)

Not yet recruiting
  • Leukemia,Myeloid, Chronic
  • Blood and bone marrow sample
  • Annecy, France
  • +15 more
Nov 10, 2023

Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

Recruiting
  • Leukemia, Chronic Myelogenous
  • Chongqing City, Chongqing, China
  • +23 more
Jan 18, 2023

Treatment Free Remission, Chronic Myeloid Leukemia Trial in Turin

Recruiting
  • Treatment Free Remission
  • Chronic Myeloid Leukemia
    • Turin, Italy
      Division of Hematology-AO Mauriziano Hospital, University of Tur
    Nov 17, 2021

    Ovarian Reserve and Fertility in Chronic Myeloid Leukemia or

    Recruiting
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +2 more
    • Cytology Specimen Collection Procedure
    • +3 more
    • Los Angeles, California
      USC / Norris Comprehensive Cancer Center
    Nov 16, 2021

    The Life After Stopping Tyrosine Kinase Inhibitors Study

    Completed
    • Leukemia, Myeloid, Chronic
    • Imatinib (Stopping their TKI)
    • +3 more
    • San Francisco, California
    • +15 more
    Jan 3, 2023

    Treatment, Stem Cell Transplantation Trial in Italy (Nilotinib, Imatinib)

    Completed
    • Treatment
    • Stem Cell Transplantation
    • Ancona, Italy
    • +34 more
    Oct 10, 2022

    Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual

    Terminated
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 1, 2020

    Leukemia, Myeloid, Chronic Trial in Germany, United States (LBH589)

    Terminated
    Has Results
    • Leukemia, Myeloid, Chronic
    • Duarte, California
    • +25 more
    Jul 14, 2021

    Myeloid Leukemia, Philadelphia Positive Trial in Worldwide (Asciminib Pediatric formulation group, Asciminib Adult formulation

    Recruiting
    • Myeloid Leukemia, Philadelphia Positive
    • Asciminib Pediatric formulation group
    • Asciminib Adult formulation group
    • Boston, Massachusetts
    • +24 more
    Jan 17, 2023

    Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Worldwide (procedure, other, drug)

    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Biospecimen Collection
    • +4 more
    • Birmingham, Alabama
    • +170 more
    Jan 30, 2023

    Myeloid Leukemia, Chronic Trial in Germany (dasatinib (SPRYCEL®))

    Active, not recruiting
    • Myeloid Leukemia, Chronic
    • dasatinib (SPRYCEL®)
    • Aachen, Germany
    • +52 more
    Jun 1, 2022

    Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Trial in Worldwide (Nilotinib + LDE225)

    Completed
    • Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
    • Nilotinib + LDE225
    • Toronto, Ontario, Canada
    • +6 more
    Dec 6, 2020

    Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in Moscow, St. Petersburg (PF-114)

    Unknown status
    • Chronic Myeloid Leukemia
    • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    • Moscow, Russian Federation
    • +2 more
    Feb 13, 2020

    Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

    Recruiting
    • Chronic Myelogenous Leukemia
    • ABL001 40mg BID
    • +2 more
    • Caba, Buenos Aires, Argentina
    • +53 more
    Jan 27, 2023